

NOV 25 2002

ATTY. DOCKET

10872/482274

SERIAL NO.

60/268,439

**LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT**

APPLICANT

FILING DATE

February 13, 2001

GROUP

Exam Init.	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS
Bu	4	6	8	3	1	9	5	Jul 28, 1987	Mullis et al.	435	6
	4	6	8	3	2	0	2	Jul 28, 1987	Mullis	435	91
	5	4	5	5	1	7	5	Oct. 3, 1995	Wittwer, et al.	435	286.1
	5	8	3	7	8	3	2	Nov. 17, 1998	Chee et al.	536	22.1
	5	8	0	7	5	2	2	Sep. 15, 1998	Brown et al.	422	50
OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)											

A simple introduction to the science of the polymerase chain reaction, PCR: Basics for beginners, Jan. 31, 01.

Adaptation Protocol for Sequence-Specific Detection of DNA with Hybridization Probes, Roche Molecular Biochemicals, Technical Note. No. 3/99.

Antin, J. et al., Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-vs-host disease in patients with hemtologic malignancies. Blood: 78: 2139, 1991.

Baldanti F, et al., Highlevels of Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J. Clin Microbiol. 38: 613, 2000.

Caplin, et al., The most direct way to monitor PCR amplification for quantification and mutation detection, Roche Moelcular Biochemicals, Biochemica - No. 1, 1999.

Choice of Suitable Probe Targets, 1 page article.

DeSilva, et al., Rapid Genotyping and Quantification on the LightCycler™with Hybridization Probes, Biochemica, No. 2, (1998).

Groen, Pamela, et al., "Development of a Quantitative EBV PCR Assay for the LightCycler System," 14 pgs, (2001).

Henry T., et al., Correlation of Epstein-Barr viral load with development of PTLD in solid organ transplant recipients. (In press). (Article Unavailable)

Ho M., et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children, Transplantation 45: 719-727, 1988.

Kenagy DN, et al., Epstein-Barr virus DNA in peripheral blood leukocytes with post-transplant lymphoproliferative disease. Transplant 60:547, 1995.

Kimura H., et al., Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J. Clin Microbiol. 37:132, 1999.

Landt, et al., Selection of Hybridization Probe Sequences for Use with the LightCycler, Roche Molecular

Biochemicals, Technical Note No. LC6/99.

182



*LightCycler Principles*, Biochem.Boehringer-Mannheim.

Loechelt, Brett J., et al., "GM-CSF as Pre-Emptive Therapy for Posttransplant EBV Disease," 3 pgs, (2001).

Lucas KG, et al., *Semiquantitative Epstein-Barr virus DNA in blood of solid organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders*. J. Clin Microbiol. 38: 613, 2000. (Article Unavailable)

Martell, M., et al., *High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA*. J. Clin. Microbiol. 1999 Feb;37(2):327-32.

Martin, PJ, et al., *Fatal Epstein-Barr virus associated proliferation of donor B cells after treatment of acute graft vs-host disease with a murine anti-T-cell antibody*. Ann Intern Med 101:310, 1984.

Mercier B., et al., *Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay*. J. Cirol Methods, 1999 Jan;77(1):1-9.

Niesters H, et al, *Development of a real-time quantitative assay for detection of Epstein-Barr virus*. J. Clin Microliol. 2000 Feb;38(2):712-5.

Papdopoulos EB, et al., *Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorder complicating allogeneic marrow transplantation*, N. Engl J. Med 330: 1185, 1994.

Rasmussen et al., *Quantitative PCR by Continuous Fluorescence Monitoring of a Double Strand DNA Specific Binding Dye*, Biochemica, No. 2, (1998).

Recombinant DNA Technology, *DNA Amplification by the Polymerase Chain Reaction*, Chapter 3, Nucleotides and Nucleic Acids.

Riddler SA, et al., *Increased levels of circulating Epstein-Barr virus (EBV) infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients*. Blood 84:972, 1994.

Rogers B, et al., *Epstein-Barr virus polymerase chain reaction and serology in pediatric post-transplant lymphoproliferative disorder: three year experience*. Pediatric & Developmental Pathology 1: 480, 1998.

Savoie A, et al., *Direct correlation between the load of Epstein-Barr virus infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease*. Blood 83: 2715, 1994.

Shapiro, RS, et al., *Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation*. Blood 71: 1234, 1988.

Starzl T, et al., *Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin steroid therapy*, Lancet I: 583, 1984.

*The LightCycler™ - the Smartest Innovation for More Efficient PCR*, Biochemica, No. 2 (1998).

University of Chicago Cancer Research Center, DNA Sequencing Facility, *The Standard Primers*, April 17, 1997 update.

*V6* Zutter MM, et al. *Epstein-Barr virus lymphoproliferation after bone marrow transplantation.* Blood 72, 520, 1988.

EXAMINER

*Baughn*

DATE CONSIDERED

*08/20/2003*

Page \_\_\_\_ of \_\_\_\_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CINlibrary/1218796.1



**RECEIVED**

*NOV 27 2002*

**TECH CENTER 1600/2900**